Literature DB >> 6084225

Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis.

R J Olk, D B Burgess, P A McCormick.   

Abstract

The visual prognosis of 148 eyes in patients with an active subfoveal or juxtafoveal subretinal neovascular membrane (SRNVM) in the presumed ocular histoplasmosis syndrome (POHS) was reviewed. Average follow-up was 39 months. One hundred twenty of 148 eyes (81.1%) had a final visual acuity worse than 20/40. One hundred three of 148 eyes (69.6%) had a final visual acuity equal to or worse than 20/200. Systemic and/or periocular steroids had no effect on final visual outcome. Factors affecting final visual outcome are described and prognosis in the fellow eye is discussed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6084225     DOI： 10.1016/s0161-6420(84)34113-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


  11 in total

1.  Presumed ocular histoplasmosis in The Netherlands--an area without histoplasmosis.

Authors:  M S Suttorp-Schulten; J G Bollemeijer; P J Bos; A Rothova
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

2.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

Review 3.  Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment.

Authors:  Narendra Dhingra; Susan Kelly; Mohammed A Majid; Claire B Bailey; Andrew D Dick
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

4.  Idiopathic sub-retinal neovascular membranes in the macula (hemorrhagic macular choroidopathy of young adults). Clinical report and effectiveness of laser treatment.

Authors:  F G Bottoni; A F Deutman
Journal:  Doc Ophthalmol       Date:  1986       Impact factor: 2.379

5.  Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression.

Authors:  T Leslie; N Lois; D Christopoulou; J A Olson; J V Forrester
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

6.  Bevacizumab in inflammatory eye disease.

Authors:  McGregor N Lott; Joyce C Schiffman; Janet L Davis
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

7.  Peripapillary choroidal neovascularisation in the context of ocular syphilis is sensitive to combination antibiotic and corticosteroid treatment.

Authors:  Konstantinos Balaskas; Stephen Spencer; Yvonne D'Souza
Journal:  Int Ophthalmol       Date:  2012-09-27       Impact factor: 2.031

8.  Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration.

Authors:  N H Victor Chong; Jason Keonin; Phil J Luthert; Christina I Frennesson; David M Weingeist; Rachel L Wolf; Robert F Mullins; Gregory S Hageman
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

9.  Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome.

Authors:  Alfredo Adán; Manuel Navarro; Ricardo P Casaroli-Marano; Santiago Ortiz; Juan José Molina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-05       Impact factor: 3.117

10.  [Intraocular injections of bevacizumab in rare indications--two cases].

Authors:  T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.